Klein Ran, Razavi Simin, Memon Rayhan, Zuckier Lionel S
Department of Medicine, Division of Nuclear Medicine, University of Ottawa.
Ottawa Hospital Research Institute.
Nucl Med Commun. 2019 Jan;40(1):30-40. doi: 10.1097/MNM.0000000000000929.
Critical clinical decisions are made on the basis of the glomerular filtration rate (GFR) measured using technetium-99m-diethylenetriaminepentaacetic acid (DTPA) administration, followed by multiple time-point plasma sampling. As GFR studies rely on few data points and produce a single result, they are prone to technical errors that may remain inconspicuous.
We describe a data analysis worksheet that provides real-time quality control (QC) indicators and evaluate our initial clinical experience.
Two hundred and forty-six consecutive GFR studies carried out at our clinics were included. Our protocol used plasma samples at 2, 3, and 4 h after injection of technetium-99m-DTPA. Duplicate plasma samples, background samples, and aliquots of an activity dilution standard were counted. Times were logged for injection and dilution standard preparation, blood sampling, and counting. Data were entered into a custom GFR analysis spreadsheet that flagged QC in real time at warning and error levels, including QC of the expected ratio between dilution standard counts-activity ratio (CARs) measurements, which was newly introduced to our clinic. The prevalence of QC events was analyzed in three phases: baseline, training, and evaluation (n=31, 69, and 146, respectively).
From the baseline and training phases (n=100), CAR reference values were determined for each of two sites. In the absence of the CAR QC indicator, errors were present in 5/31 (16%) examinations, but with QC indication decreased to 7/146 (5%) (P<0.05), suggesting that the real-time QC information guided the technologists to ensure proper standard preparation and sample handling, as intended. Improvements in other QC measures were also noted, resulting in an overall error rate reduction from 23 to 8%.
Real-time analysis of redundant information as a component of the GFR worksheet ensures quality results, but training of technologists and interpreting physicians is essential for optimal utilization of these QC indicators.
关键临床决策是基于使用锝-99m-二乙三胺五乙酸(DTPA)给药并进行多个时间点血浆采样来测量的肾小球滤过率(GFR)做出的。由于GFR研究依赖的数据点较少且产生单一结果,它们容易出现可能不明显的技术误差。
我们描述了一种提供实时质量控制(QC)指标的数据分析工作表,并评估我们的初步临床经验。
纳入了在我们诊所进行的246项连续GFR研究。我们的方案在注射锝-99m-DTPA后2、3和4小时采集血浆样本。对重复血浆样本、背景样本和活性稀释标准品的等分试样进行计数。记录注射和稀释标准品制备、采血和计数的时间。数据被输入到一个定制的GFR分析电子表格中,该表格在警告和错误级别实时标记QC,包括新引入到我们诊所的稀释标准计数-活性比(CARs)测量之间预期比率的QC。在三个阶段分析了QC事件的发生率:基线期、培训期和评估期(分别为n = 31、69和146)。
从基线期和培训期(n = 100)确定了两个站点各自的CAR参考值。在没有CAR QC指标的情况下,5/31(16%)的检查存在误差,但有QC指标时降至7/146(5%)(P<0.05),这表明实时QC信息指导技术人员按预期确保正确的标准品制备和样本处理。还注意到其他QC措施有所改进,总体错误率从23%降至8%。
作为GFR工作表组成部分的冗余信息实时分析可确保获得高质量结果,但技术人员和解读医生的培训对于这些QC指标的最佳利用至关重要。